You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • Reference number: TA226
  • Published:  22 June 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Lymphoma (follicular non-Hodgkin's ) - rituximab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Lymphoma (follicular non-Hodgkin's ) - rituximab:
response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) Lymphoma (follicular non-Hodgkin's ) - rituximab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
24 May 2011
(1.5 Mb 27 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 20 May 2011

Back to top